AstraZeneca agreed to license global rights to Dizal Pharmaceutical’s marketed lung cancer drug Zegfrovy (sunvozertinib) in a deal valued up to $1.5 billion, extending AstraZeneca’s reach in EGFR-driven non-small cell lung cancer. The agreement includes $600 million upfront and additional development and sales milestones. Zegfrovy is already approved in the U.S. and China for EGFR exon 20 insertion NSCLC after prior systemic therapy, and Dizal is pursuing expansion into first-line treatment based on positive phase 3 results from the WU-KONG28 trial. Breakthrough Therapy designations were granted in the first-line setting. The licensing structure gives AstraZeneca worldwide development and commercialization rights, effectively folding Dizal’s exon 20 program into AstraZeneca’s established oncology footprint. AstraZeneca’s timing follows another large partner deal tied to lung cancer assets from China-origin portfolios. For developers and investors, the transaction reinforces the premium placed on oral targeted oncology drugs with biomarker-defined populations and late-stage clinical validation.